25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Bellerophon Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Bellerophon together

I guess you are interested in Bellerophon Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Bellerophon Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Bellerophon Therapeutics Inc

I send you an email if I find something interesting about Bellerophon Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Bellerophon (30 sec.)










1.2. What can you expect buying and holding a share of Bellerophon? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.21
Expected worth in 1 year
$-6.03
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-6.24
Return On Investment
-15,601.8%

For what price can you sell your share?

Current Price per Share
$0.04
Expected price per share
$0.037 - $0.055
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Bellerophon (5 min.)




Live pricePrice per Share (EOD)
$0.04
Intrinsic Value Per Share
$-22.56 - $-5.12
Total Value Per Share
$-22.36 - $-4.91

2.2. Growth of Bellerophon (5 min.)




Is Bellerophon growing?

Current yearPrevious yearGrowGrow %
How rich?$2.5m$21.6m-$19m-753.2%

How much money is Bellerophon making?

Current yearPrevious yearGrowGrow %
Making money-$19.8m-$17.7m-$2m-10.5%
Net Profit Margin-351.6%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Bellerophon (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Bellerophon?

Welcome investor! Bellerophon's management wants to use your money to grow the business. In return you get a share of Bellerophon.

First you should know what it really means to hold a share of Bellerophon. And how you can make/lose money.

Speculation

The Price per Share of Bellerophon is $0.04. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bellerophon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bellerophon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.21. Based on the TTM, the Book Value Change Per Share is $-1.56 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.36 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bellerophon.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.62-4,052.9%-1.62-4,052.9%-1.45-3,628.8%-1.19-2,974.3%-2.59-6,464.3%
Usd Book Value Change Per Share-1.56-3,900.4%-1.56-3,900.4%-1.36-3,398.7%0.08209.6%0.11267.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.56-3,900.4%-1.56-3,900.4%-1.36-3,398.7%0.08209.6%0.11267.1%
Usd Price Per Share0.90-0.90-3.10-2.36-1.79-
Price to Earnings Ratio-0.56--0.56--2.14--0.57--0.45-
Price-to-Total Gains Ratio-0.58--0.58--2.28--3.03--1.54-
Price to Book Ratio4.34-4.34-1.75-2.39-0.13-
Price-to-Total Gains Ratio-0.58--0.58--2.28--3.03--1.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.04
Number of shares25000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.560.08
Usd Total Gains Per Share-1.560.08
Gains per Quarter (25000 shares)-39,004.382,096.04
Gains per Year (25000 shares)-156,017.538,384.15
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-156018-156028083848374
20-312035-31204601676816758
30-468053-46806402515225142
40-624070-62408203353733526
50-780088-78010004192141910
60-936105-93611805030550294
70-1092123-109213605868958678
80-1248140-124815406707367062
90-1404158-140417207545775446
100-1560175-156019008384283830

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%1.09.00.010.0%1.010.00.09.1%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%4.07.00.036.4%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.011.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%4.07.00.036.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Bellerophon Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.560-1.5600%-1.359-13%0.084-1961%0.107-1560%
Book Value Per Share--0.2070.2070%1.767-88%1.142-82%1.010-79%
Current Ratio--1.4001.4000%5.039-72%2.945-52%3.024-54%
Debt To Asset Ratio--0.6810.6810%0.196+248%0.526+29%0.995-32%
Debt To Equity Ratio--2.1312.1310%0.243+777%1.820+17%1.047+104%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--12937340.00012937340.0000%57401060.000-77%40815157.572-68%36866654.613-65%
Eps---1.621-1.6210%-1.452-10%-1.190-27%-2.586+59%
Ev To Ebitda Ratio---0.583-0.5830%-2.847+388%-1.672+187%-0.749+28%
Ev To Sales Ratio--2.2942.2940%infnan%infnan%infnan%
Free Cash Flow Per Share---1.453-1.4530%-1.866+28%-1.454+0%-2.404+66%
Free Cash Flow To Equity Per Share---1.456-1.4560%-1.866+28%-0.410-72%0.058-2620%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---5.119--------
Intrinsic Value_10Y_min---22.564--------
Intrinsic Value_1Y_max---1.254--------
Intrinsic Value_1Y_min---2.392--------
Intrinsic Value_3Y_max---3.202--------
Intrinsic Value_3Y_min---7.117--------
Intrinsic Value_5Y_max---4.470--------
Intrinsic Value_5Y_min---11.728--------
Market Cap489304.000-2150%11009340.00011009340.0000%37921060.000-71%28920557.572-62%21873723.690-50%
Net Profit Margin---3.516-3.5160%--100%-0.703-80%-0.352-90%
Operating Margin---3.945-3.9450%--100%-0.789-80%-0.394-90%
Operating Ratio--3.9803.9800%-+100%0.796+400%0.398+900%
Pb Ratio0.193-2150%4.3454.3450%1.754+148%2.393+82%0.135+3127%
Pe Ratio-0.025+96%-0.555-0.5550%-2.136+285%-0.566+2%-0.445-20%
Price Per Share0.040-2150%0.9000.9000%3.100-71%2.364-62%1.788-50%
Price To Free Cash Flow Ratio-0.028+96%-0.620-0.6200%-1.662+168%-1.470+137%-1.050+69%
Price To Total Gains Ratio-0.026+96%-0.577-0.5770%-2.280+295%-3.025+424%-1.535+166%
Quick Ratio--1.4321.4320%4.896-71%2.879-50%3.094-54%
Return On Assets---2.499-2.4990%-0.661-74%-0.902-64%-2.685+7%
Return On Equity---7.826-7.8260%-0.821-90%-2.452-69%-1.772-77%
Total Gains Per Share---1.560-1.5600%-1.359-13%0.084-1961%0.107-1560%
Usd Book Value--2534000.0002534000.0000%21619000.000-88%13969800.000-82%12278300.000-79%
Usd Book Value Change Per Share---1.560-1.5600%-1.359-13%0.084-1961%0.107-1560%
Usd Book Value Per Share--0.2070.2070%1.767-88%1.142-82%1.010-79%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.621-1.6210%-1.452-10%-1.190-27%-2.586+59%
Usd Free Cash Flow---17770000.000-17770000.0000%-22821000.000+28%-17781200.000+0%-29712300.000+67%
Usd Free Cash Flow Per Share---1.453-1.4530%-1.866+28%-1.454+0%-2.404+66%
Usd Free Cash Flow To Equity Per Share---1.456-1.4560%-1.866+28%-0.410-72%0.058-2620%
Usd Market Cap489304.000-2150%11009340.00011009340.0000%37921060.000-71%28920557.572-62%21873723.690-50%
Usd Price Per Share0.040-2150%0.9000.9000%3.100-71%2.364-62%1.788-50%
Usd Profit---19831000.000-19831000.0000%-17756000.000-10%-14553600.000-27%-31953100.000+61%
Usd Revenue--5640000.0005640000.0000%-+100%1128000.000+400%564000.000+900%
Usd Total Gains Per Share---1.560-1.5600%-1.359-13%0.084-1961%0.107-1560%
 EOD+3 -5MRQTTM+0 -0YOY+9 -265Y+7 -2810Y+13 -22

3.3 Fundamental Score

Let's check the fundamental score of Bellerophon Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.025
Price to Book Ratio (EOD)Between0-10.193
Net Profit Margin (MRQ)Greater than0-3.516
Operating Margin (MRQ)Greater than0-3.945
Quick Ratio (MRQ)Greater than11.432
Current Ratio (MRQ)Greater than11.400
Debt to Asset Ratio (MRQ)Less than10.681
Debt to Equity Ratio (MRQ)Less than12.131
Return on Equity (MRQ)Greater than0.15-7.826
Return on Assets (MRQ)Greater than0.05-2.499
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Bellerophon Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.851
Ma 20Greater thanMa 500.043
Ma 50Greater thanMa 1000.039
Ma 100Greater thanMa 2000.039
OpenGreater thanClose0.040
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Bellerophon Therapeutics Inc

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Fundamental data was last updated by Penke on 2024-12-02 09:44:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Bellerophon earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Bellerophon to the Biotechnology industry mean.
  • A Net Profit Margin of -351.6% means that $-3.52 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bellerophon Therapeutics Inc:

  • The MRQ is -351.6%. The company is making a huge loss. -2
  • The TTM is -351.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-351.6%TTM-351.6%0.0%
TTM-351.6%YOY--351.6%
TTM-351.6%5Y-70.3%-281.3%
5Y-70.3%10Y-35.2%-35.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-351.6%-112.2%-239.4%
TTM-351.6%-221.4%-130.2%
YOY--210.0%+210.0%
5Y-70.3%-342.2%+271.9%
10Y-35.2%-464.5%+429.3%
4.3.1.2. Return on Assets

Shows how efficient Bellerophon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bellerophon to the Biotechnology industry mean.
  • -249.9% Return on Assets means that Bellerophon generated $-2.50 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bellerophon Therapeutics Inc:

  • The MRQ is -249.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -249.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-249.9%TTM-249.9%0.0%
TTM-249.9%YOY-66.1%-183.8%
TTM-249.9%5Y-90.2%-159.7%
5Y-90.2%10Y-268.5%+178.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-249.9%-11.3%-238.6%
TTM-249.9%-11.7%-238.2%
YOY-66.1%-11.3%-54.8%
5Y-90.2%-12.7%-77.5%
10Y-268.5%-14.1%-254.4%
4.3.1.3. Return on Equity

Shows how efficient Bellerophon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bellerophon to the Biotechnology industry mean.
  • -782.6% Return on Equity means Bellerophon generated $-7.83 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bellerophon Therapeutics Inc:

  • The MRQ is -782.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -782.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-782.6%TTM-782.6%0.0%
TTM-782.6%YOY-82.1%-700.5%
TTM-782.6%5Y-245.2%-537.4%
5Y-245.2%10Y-177.2%-68.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-782.6%-14.2%-768.4%
TTM-782.6%-15.9%-766.7%
YOY-82.1%-14.3%-67.8%
5Y-245.2%-18.5%-226.7%
10Y-177.2%-19.3%-157.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Bellerophon Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Bellerophon is operating .

  • Measures how much profit Bellerophon makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bellerophon to the Biotechnology industry mean.
  • An Operating Margin of -394.5% means the company generated $-3.94  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bellerophon Therapeutics Inc:

  • The MRQ is -394.5%. The company is operating very inefficient. -2
  • The TTM is -394.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-394.5%TTM-394.5%0.0%
TTM-394.5%YOY--394.5%
TTM-394.5%5Y-78.9%-315.6%
5Y-78.9%10Y-39.4%-39.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-394.5%-222.9%-171.6%
TTM-394.5%-310.7%-83.8%
YOY--223.5%+223.5%
5Y-78.9%-387.1%+308.2%
10Y-39.4%-498.5%+459.1%
4.3.2.2. Operating Ratio

Measures how efficient Bellerophon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.98 means that the operating costs are $3.98 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Bellerophon Therapeutics Inc:

  • The MRQ is 3.980. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.980. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.980TTM3.9800.000
TTM3.980YOY-+3.980
TTM3.9805Y0.796+3.184
5Y0.79610Y0.398+0.398
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9802.465+1.515
TTM3.9803.253+0.727
YOY-3.298-3.298
5Y0.7964.788-3.992
10Y0.3986.494-6.096
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Bellerophon Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Bellerophon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.40 means the company has $1.40 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Bellerophon Therapeutics Inc:

  • The MRQ is 1.400. The company is just able to pay all its short-term debts.
  • The TTM is 1.400. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.400TTM1.4000.000
TTM1.400YOY5.039-3.639
TTM1.4005Y2.945-1.545
5Y2.94510Y3.024-0.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4003.637-2.237
TTM1.4003.890-2.490
YOY5.0394.666+0.373
5Y2.9455.953-3.008
10Y3.0246.277-3.253
4.4.3.2. Quick Ratio

Measures if Bellerophon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bellerophon to the Biotechnology industry mean.
  • A Quick Ratio of 1.43 means the company can pay off $1.43 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bellerophon Therapeutics Inc:

  • The MRQ is 1.432. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.432. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.432TTM1.4320.000
TTM1.432YOY4.896-3.464
TTM1.4325Y2.879-1.447
5Y2.87910Y3.094-0.214
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4323.086-1.654
TTM1.4323.451-2.019
YOY4.8964.456+0.440
5Y2.8795.931-3.052
10Y3.0946.436-3.342
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Bellerophon Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Bellerophon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bellerophon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.68 means that Bellerophon assets are financed with 68.1% credit (debt) and the remaining percentage (100% - 68.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bellerophon Therapeutics Inc:

  • The MRQ is 0.681. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.681. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.681TTM0.6810.000
TTM0.681YOY0.196+0.485
TTM0.6815Y0.526+0.154
5Y0.52610Y0.995-0.469
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6810.350+0.331
TTM0.6810.344+0.337
YOY0.1960.310-0.114
5Y0.5260.365+0.161
10Y0.9950.382+0.613
4.5.4.2. Debt to Equity Ratio

Measures if Bellerophon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bellerophon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 213.1% means that company has $2.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bellerophon Therapeutics Inc:

  • The MRQ is 2.131. The company is just not able to pay all its debts with equity.
  • The TTM is 2.131. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.131TTM2.1310.000
TTM2.131YOY0.243+1.888
TTM2.1315Y1.820+0.311
5Y1.82010Y1.047+0.773
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1310.394+1.737
TTM2.1310.432+1.699
YOY0.2430.380-0.137
5Y1.8200.451+1.369
10Y1.0470.490+0.557
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Bellerophon generates.

  • Above 15 is considered overpriced but always compare Bellerophon to the Biotechnology industry mean.
  • A PE ratio of -0.56 means the investor is paying $-0.56 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bellerophon Therapeutics Inc:

  • The EOD is -0.025. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.555. Based on the earnings, the company is expensive. -2
  • The TTM is -0.555. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.025MRQ-0.555+0.530
MRQ-0.555TTM-0.5550.000
TTM-0.555YOY-2.136+1.581
TTM-0.5555Y-0.566+0.011
5Y-0.56610Y-0.445-0.121
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.025-2.253+2.228
MRQ-0.555-2.411+1.856
TTM-0.555-3.149+2.594
YOY-2.136-3.274+1.138
5Y-0.566-6.143+5.577
10Y-0.445-6.785+6.340
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bellerophon Therapeutics Inc:

  • The EOD is -0.028. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.620. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.620. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.028MRQ-0.620+0.592
MRQ-0.620TTM-0.6200.000
TTM-0.620YOY-1.662+1.042
TTM-0.6205Y-1.470+0.850
5Y-1.47010Y-1.050-0.420
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.028-3.009+2.981
MRQ-0.620-3.259+2.639
TTM-0.620-3.730+3.110
YOY-1.662-4.574+2.912
5Y-1.470-8.371+6.901
10Y-1.050-9.287+8.237
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Bellerophon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.34 means the investor is paying $4.34 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Bellerophon Therapeutics Inc:

  • The EOD is 0.193. Based on the equity, the company is cheap. +2
  • The MRQ is 4.345. Based on the equity, the company is fair priced.
  • The TTM is 4.345. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD0.193MRQ4.345-4.152
MRQ4.345TTM4.3450.000
TTM4.345YOY1.754+2.591
TTM4.3455Y2.393+1.952
5Y2.39310Y0.135+2.258
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.1931.979-1.786
MRQ4.3452.051+2.294
TTM4.3452.365+1.980
YOY1.7542.455-0.701
5Y2.3933.726-1.333
10Y0.1354.378-4.243
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Bellerophon Therapeutics Inc.

4.8.1. Institutions holding Bellerophon Therapeutics Inc

Institutions are holding 8.394% of the shares of Bellerophon Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Acadian Asset Management LLC1.63170199600-183578-47.9093
2023-09-30Citadel Advisors Llc0.3492042717427170
2023-12-31Raymond James & Associates0.081701000000
2023-12-31State Street Corporation000-30127-100
2023-12-31Susquehanna International Group, LLP000-15313-100
2023-12-31Wells Fargo & Co000-180066-100
2023-12-31Tower Research Capital LLC000-7135-100
2023-09-30Financial Gravity Wealth, Inc.000-26087-100
2023-12-31Northern Trust Corp000-30251-100
2023-12-31GPS Wealth Strategies Group, LLC000-38-100
2023-12-31PFS Partners, LLC000-6000-100
2023-12-31Morgan Stanley - Brokerage Accounts000-33-100
2023-12-31U.S. Bancorp000-1221-100
2023-12-31Two Sigma Investments LLC000-113911-100
2023-09-30Virtu Financial LLC000-25870-100
2023-12-31Advisor Group Holdings, Inc.000-557-100
2023-12-31Renaissance Technologies Corp000-59499-100
2023-12-31Group One Trading, LP000-2100-100
2023-12-31Qube Research & Technologies000-52-100
2023-12-31Vanguard Group Inc000-145810-100
Total 2.06260252317-784931-311.1%

4.9.2. Funds holding Bellerophon Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30BlackRock Extended Mkt Composite0.21080.00012579000
2023-12-31NT Quality SCC US Fund - L0.04010.0001490100
2023-12-31NT Quality Small Cap Core0.04010.0001490100
2024-02-29Dimensional US Core Equity 2 ETF0.03690451700
Total 0.32790.00034010900.0%

5.3. Insider Transactions

Insiders are holding 15.027% of the shares of Bellerophon Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-10-13Puissance Capital Management LSELL10768410.1
2023-06-07Life Science Opportu PuissanceSELL1344210.83
2023-05-18Bobae KimSELL945510
2023-05-18Life Science Opportu PuissanceSELL5600009.46
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets7,935
Total Liabilities5,401
Total Stockholder Equity2,534
 As reported
Total Liabilities 5,401
Total Stockholder Equity+ 2,534
Total Assets = 7,935

Assets

Total Assets7,935
Total Current Assets7,563
Long-term Assets372
Total Current Assets
Cash And Cash Equivalents 6,924
Short-term Investments 405
Other Current Assets 234
Total Current Assets  (as reported)7,563
Total Current Assets  (calculated)7,563
+/-0
Long-term Assets
Property Plant Equipment 186
Long-term Assets Other 186
Long-term Assets  (as reported)372
Long-term Assets  (calculated)372
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,401
Long-term Liabilities1,433
Total Stockholder Equity2,534
Total Current Liabilities
Short-term Debt 203
Accounts payable 1,230
Other Current Liabilities 3,968
Total Current Liabilities  (as reported)5,401
Total Current Liabilities  (calculated)5,401
+/-0
Long-term Liabilities
Capital Lease Obligations 203
Long-term Liabilities  (as reported)1,433
Long-term Liabilities  (calculated)203
+/- 1,230
Total Stockholder Equity
Common Stock96
Retained Earnings -252,078
Other Stockholders Equity 254,516
Total Stockholder Equity (as reported)2,534
Total Stockholder Equity (calculated)2,534
+/-0
Other
Capital Stock96
Cash and Short Term Investments 7,329
Common Stock Shares Outstanding 9,551
Liabilities and Stockholders Equity 7,935
Net Debt -6,721
Net Invested Capital 2,534
Net Working Capital 2,162
Property Plant and Equipment Gross 186
Short Long Term Debt Total 203



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
> Total Assets 
3,349
3,636
33,391
38,409
29,702
36,810
18,360
13,108
50,239
26,875
7,935
7,93526,87550,23913,10818,36036,81029,70238,40933,3913,6363,349
   > Total Current Assets 
319
1,552
27,681
29,452
26,505
35,580
17,396
10,382
48,080
25,459
7,563
7,56325,45948,08010,38217,39635,58026,50529,45227,6811,552319
       Cash And Cash Equivalents 
0
0
16,815
6,260
14,453
28,823
16,645
9,874
47,557
24,736
6,924
6,92424,73647,5579,87416,64528,82314,4536,26016,81500
       Short-term Investments 
0
0
9,264
17,807
5,571
2,996
0
0
0
0
405
40500002,9965,57117,8079,26400
       Other Current Assets 
319
1,552
10,866
5,385
6,331
3,359
650
508
523
723
234
2347235235086503,3596,3315,38510,8661,552319
   > Long-term Assets 
3,030
2,084
5,710
8,957
3,197
1,230
964
2,726
2,159
1,416
372
3721,4162,1592,7269641,2303,1978,9575,7102,0843,030
       Property Plant Equipment 
1,703
2,084
1,696
1,799
1,399
1,026
664
2,426
1,673
930
186
1869301,6732,4266641,0261,3991,7991,6962,0841,703
       Other Assets 
1,327
0
4,014
7,158
1,798
204
300
300
1,990
486
0
04861,9903003002041,7987,1584,01401,327
> Total Liabilities 
14,465
19,373
10,454
8,073
11,710
39,404
14,504
9,517
11,990
5,256
5,401
5,4015,25611,9909,51714,50439,40411,7108,07310,45419,37314,465
   > Total Current Liabilities 
11,211
13,992
10,454
8,073
6,495
7,079
7,539
7,584
10,433
5,052
5,401
5,4015,05210,4337,5847,5397,0796,4958,07310,45413,99211,211
       Short-term Debt 
0
0
0
0
5,215
0
0
1,316
1,408
1,504
203
2031,5041,4081,316005,2150000
       Accounts payable 
1,487
1,368
376
1,613
2,807
3,853
2,755
3,106
3,725
1,192
1,230
1,2301,1923,7253,1062,7553,8532,8071,6133761,3681,487
       Other Current Liabilities 
9,724
12,624
10,078
6,460
3,688
3,226
4,784
3,162
5,300
2,356
3,968
3,9682,3565,3003,1624,7843,2263,6886,46010,07812,6249,724
   > Long-term Liabilities 
3,254
5,381
0
0
5,215
32,325
6,965
1,933
1,557
204
1,433
1,4332041,5571,9336,96532,3255,215005,3813,254
       Other Liabilities 
3,254
5,381
0
0
5,215
32,325
6,965
274
601
1
0
016012746,96532,3255,215005,3813,254
       Deferred Long Term Liability 
0
0
2,466
0
1,406
0
0
0
0
0
0
0000001,40602,46600
> Total Stockholder Equity
-11,116
-15,737
22,937
30,336
17,992
-2,594
3,856
3,591
38,249
21,619
2,534
2,53421,61938,2493,5913,856-2,59417,99230,33622,937-15,737-11,116
   Common Stock
0
0
77,156
131
317
569
587
46
95
95
96
9695954658756931713177,15600
   Retained Earnings -252,078-232,247-214,491-189,763-176,496-179,310-124,492-100,678-54,219-176,515-114,517
   Accumulated Other Comprehensive Income 000-2,212-1,864-4-2,024-19-1,247-859-156
   Capital Surplus 
0
0
0
130,902
142,167
176,151
179,765
193,308
252,645
0
0
00252,645193,308179,765176,151142,167130,902000
   Treasury Stock00000000000
   Other Stockholders Equity 
103,557
161,637
78,403
130,902
142,167
176,151
179,765
193,308
252,645
253,771
254,516
254,516253,771252,645193,308179,765176,151142,167130,90278,403161,637103,557



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue5,640
Cost of Revenue--
Gross Profit-5,640
 
Operating Income (+$)
Gross Profit-
Operating Expense-16,676
Operating Income-11,036-16,676
 
Operating Expense (+$)
Research Development9,708
Selling General Administrative6,968
Selling And Marketing Expenses-
Operating Expense16,67616,676
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-365
Net Interest Income365
 
Pretax Income (+$)
Operating Income-11,036
Net Interest Income365
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-10,530-11,036
EBIT - interestExpense = 0
-9,253
-9,253
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--10,530
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-10,530
Tax Provision--1,277
Net Income From Continuing Ops-9,253-9,253
Net Income-9,253
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--365
 

Technical Analysis of Bellerophon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bellerophon. The general trend of Bellerophon is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bellerophon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Bellerophon Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.055 < 0.055 < 0.055.

The bearish price targets are: 0.037 > 0.037 > 0.037.

Tweet this
Bellerophon Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Bellerophon Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Bellerophon Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Bellerophon Therapeutics Inc. The current macd is 0.0023387.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bellerophon price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Bellerophon. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Bellerophon price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Bellerophon Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartBellerophon Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Bellerophon Therapeutics Inc. The current adx is 68.49.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Bellerophon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Bellerophon Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Bellerophon Therapeutics Inc. The current sar is 0.07309232.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Bellerophon Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Bellerophon Therapeutics Inc. The current rsi is 43.85. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Bellerophon Therapeutics Inc Daily Relative Strength Index (RSI) ChartBellerophon Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Bellerophon Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bellerophon price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Bellerophon Therapeutics Inc Daily Stochastic Oscillator ChartBellerophon Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Bellerophon Therapeutics Inc. The current cci is -24.68496461.

Bellerophon Therapeutics Inc Daily Commodity Channel Index (CCI) ChartBellerophon Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Bellerophon Therapeutics Inc. The current cmo is -25.52991297.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Bellerophon Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartBellerophon Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Bellerophon Therapeutics Inc. The current willr is -83.33333333.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Bellerophon Therapeutics Inc Daily Williams %R ChartBellerophon Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Bellerophon Therapeutics Inc.

Bellerophon Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Bellerophon Therapeutics Inc. The current atr is 0.00315618.

Bellerophon Therapeutics Inc Daily Average True Range (ATR) ChartBellerophon Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Bellerophon Therapeutics Inc. The current obv is 87,525,233.

Bellerophon Therapeutics Inc Daily On-Balance Volume (OBV) ChartBellerophon Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Bellerophon Therapeutics Inc. The current mfi is 55.19.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Bellerophon Therapeutics Inc Daily Money Flow Index (MFI) ChartBellerophon Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Bellerophon Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-13MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

Bellerophon Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Bellerophon Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.851
Ma 20Greater thanMa 500.043
Ma 50Greater thanMa 1000.039
Ma 100Greater thanMa 2000.039
OpenGreater thanClose0.040
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Bellerophon with someone you think should read this too:
  • Are you bullish or bearish on Bellerophon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bellerophon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Bellerophon Therapeutics Inc

I send you an email if I find something interesting about Bellerophon Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Bellerophon Therapeutics Inc.

Receive notifications about Bellerophon Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.